Lumosa Therapeutics Co., Ltd.'s board approved the exclusive licensing agreement of LT1001, a long-acting analgesic injection, with India?s Gufic Biosciences Ltd. (Gufic). Lumosa is responsible for supplying LT1001 to Gufic while Gufic is responsible for the clinical trials, registration, marketing, and sales of LT1001 in India.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
172 TWD | -.--% | +3.30% | +151.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+151.83% | 872M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- 6535 Stock
- News Lumosa Therapeutics Co., Ltd.
- Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection